


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/226,044		
		Filing Date	January 5, 1999		
		First Named Inventor	Allan S. Hoffman		
		Group Art Unit	1615		
		Examiner Name			
Sheet	2	of	4	Attorney Docket Number	UWS 102 (OTT 2219-2744 DL)



OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
L		ABELEV, "Alpha-fetoprotein in ontogenesis and its association with malignant tumors," <i>Adv. Cancer Res.</i> 14:295-350 (1971).	
		ANDERSON, et al., "Enhanced in vitro tumor cell retention and internalization of antibody derivatized with synthetic peptides," <i>Bioconjug Chem.</i> 4(1):10-8 (1993).	
		BUSCHLE, et al., "Receptor-mediated gene transfer into human T lymphocytes via binding of DNA/CD3 antibody particles to the CD3 T cell receptor complex," <i>Hum Gene Ther.</i> 6(6):753-61 (1995).	
		CHOI, et al. "Lactose-poly(ethylene glycol)-grafted poly-L-lysine as hepatoma cell-targeted gene carrier," <i>Bioconjug Chem.</i> 9(6):708-18 (1998).	
		DONBROW, Ed., <i>Microcapsules and Nanoparticles in Medicine and Pharmacy</i> CRC Press:Boca Raton, 1992.	
		GEISOW, "Fluorescein conjugates as indicators of subcellular pH. A critical evaluation," <i>Experimental Cell Research</i> 150:29-35 (1984)	
		GOLD, et al., "Specific carcinoembryonic antigens of the human digestive system," <i>J. Exp. Med.</i> 122:467-481 (1965).	
		GUY, "Current status and future prospects of transdermal drug delivery," <i>Pharm Res.</i> 13(12):1765-9 (1996).	
		HAENSLER, et al., "Polyamidoamine cascade polymers mediate efficient transfection of cells in culture," <i>Bioconjugate Chem.</i> 4: 372-379 (1993).	
		HUGHES, et al., "Evaluation of adjuvants that enhance the effectiveness of antisense oligodeoxynucleotides," <i>Pharm Res.</i> 13(3):404-10 (1996).	

Examiner's Signature		Date Considered	3-2-99
----------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/226,044		
		Filing Date	January 5, 1999		
		First Named Inventor	Allan S. Hoffman		
		Group Art Unit	1615		
		Examiner Name			
Sheet	3	of	4	Attorney Docket Number	UWS 102 (OTT 2219-2744 DL)

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
K		KIRCHEIS, et al., "Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery," <i>Gene Ther.</i> 4(5):409-18 (1997).	
		KOST, et al., "Responsive polymer systems for controlled delivery of therapeutics," <i>TIBTECH</i> 10:127-131 (1992).	
		PAWLAK, et al., "Template-assembled melittin: structural and functional characterization of a designed, synthetic channel-forming protein," <i>Protein Science</i> 3:1788-1805 (1994).	
		PERALES, et al., "An evaluation of receptor-mediated gene transfer using synthetic DNA-ligand complexes," <i>Eur J Biochem.</i> 226(2):255-66 (1994).	
		PLANK, et al., "The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems," <i>J. Biol. Chem</i> 269: 12918-12924 (1994).	
		PRAUSNITZ, et al., "Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery," <i>Proc Natl Acad Sci U S A.</i> 90(22):10504-8 (1993).	
		PRAUSNITZ, et al., "Reversible skin permeabilization for transdermal delivery of macromolecules," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 14:455-483 (1997).	
		PRAUSNITZ, et al., "Transdermal delivery of heparin by skin electroporation," <i>Biotechnology (N Y)</i> . 13(11):1205-9 (1995).	
		PRESS, et al., "Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes," <i>Cancer Research</i> 48:2249-2257 (1988).	
		ROSS, et al., "Gene therapy in the United States: a five-year status report," <i>Hum Gene Ther.</i> 7(14):1781-90 (1996).	


Examiner's Signature		Date Considered	3-27
-------------------------	--	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/226,044		
		Filing Date	January 5, 1999		
		First Named Inventor	Allan S. Hoffman		
		Group Art Unit	1615		
		Examiner Name			
Sheet	4	of	4	Attorney Docket Number	UWS 102 (OTT 2219-2744 DL)

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
L		THOMAS, et al., "Polyelectrolyte-sensitized phospholipid vesicles," <i>Acc. Chem. Res.</i> 25: 336-342 (1992).	
		THOMAS, et al., "Membrane solubilization by a hydrophobic polyelectrolyte: surface activity and membrane binding," <i>Biophysical Journal</i> 67:1101-1106 (1994).	
		TOLSTIKOV, et al., "Influence of endosome-destabilizing peptides on efficacy of anti-HIV immunotoxins," <i>Bioconjug Chem.</i> 8(1):38-43 (1997).	
		VINOGRADOV, et al., "Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides," <i>Bioconjug Chem.</i> 9(6):805-12 (1998).	
		WANG, et al., "Delivery of antisense oligonucleotides using HPMA polymer: synthesis of A thiol polymer and its conjugation to water-soluble molecules," <i>Bioconjug Chem.</i> 9(6):749-57 (1998).	
		WEAVER, et al., "Electroporation: A general phenomenon for manipulating cells and tissues," <i>J Cell Biochem.</i> 51(4):426-35 (1993).	
✓		WILDER, et al., "Radioimmunotherapy: recent results and future directions," <i>J. Clin. Oncol.</i> 14:1383-1400 (1996).	

Examiner's Signature		Date Considered	3-20
-------------------------	--	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.